Radio-ablative iodine therapy for Thyrotoxicosis: The Universiti Kebangsaan Malaysia Medical Centre (UKMMC) experience

Shahar, Mohammad Arif and Omar, Ahmad Marzuki and Abd Aziz, Aini and AR, Anilah and Ooi, CP and M., Azura Dina and Zainuddin, Suehazlyn and Abd Wahab, Norasyikin and Mustafa, Norlaila and Sukor, Norlela and Kamaruddin, Nor Azmi (2013) Radio-ablative iodine therapy for Thyrotoxicosis: The Universiti Kebangsaan Malaysia Medical Centre (UKMMC) experience. Journal of the ASEAN Federation of Endocrine Societies, 28 (2). p. 94. ISSN 0857-1074 (print) 2308-118X (online)

	PDF (Radio-ablative iodine therapy for Thyrotoxicosis: The Universiti Kebangsaan Malaysia Medical Centre (UKMMC) experience) Restricted to Registered users only Download (1MB) | Request a copy
	PDF (Radio-ablative iodine therapy for Thyrotoxicosis: The Universiti Kebangsaan Malaysia Medical Centre (UKMMC) experience) Restricted to Repository staff only Download (3MB) | Request a copy
	PDF (Radio-ablative iodine therapy for Thyrotoxicosis: The Universiti Kebangsaan Malaysia Medical Centre (UKMMC) experience) Restricted to Repository staff only Download (2MB) | Request a copy

Abstract

Background: Radio-ablative iodine (RAI) is one of the treatment of choice for thyrotoxicosis. This study was done to determine the remission rate of thyrotoxicosis after radio-active iodine-131 (RAI) therapy and the factors associated with repeat RAI therapy at our centre. Methods: This was a retrospective analysis of 69 thyrotoxic patients who received RAI therapy from January 2011 until December 2011 in UKM Medical Centre. They were followed up for a period of two years. Data was analyzed using SPSS v.20. Results: Sixty-nine patients received RAI therapy in 2011. The mean age of the patients was 42.1 ± 12.4 years. Mean thyroxine level prior to RAI was 28.9 ± 12.8 pmol/L, and majority (80.3%) had suppressed TSH (<0.01 mIU/L) while 19.7% had low but detectable TSH (0.01-0.3 mIU/L). Ten percent of patient received second RAI within the 2 years follow-up period. Fifty-five percent of patients received 12 mCi of RAI, 24.6% and 20.3% received 10 and 15 mCi respectively. Fifty-two percent of patient remained hyperthyroid at 6 months post RAI (62% have suppressed TSH, 38% had detectable low TSH). Eighteen percent (17.9%) of patients became euthyroid and one third (30.4%) became hypothyroid at 6 months. At 12 months 62.7% of patient went into remission where 37.5% of them were euthyroid and 62.5% were hypothyroid. We did not find any difference between those who received single RAI compared to second RAI in terms of age, ethnicity, gender, anti-thyroglobulin and anti-thyroid peroxidase titre, or free thyroxine (T4) and TSH level prior to the RAI. Conclusions: The percentage of remission after RAI therapy at our centre is 48% at 6 months and 62.7% at 12 months. The requirement for second RAI was not associated with age, ethnicity, gender, anti-thyroglobulin and anti-thyroid peroxidase titre, free T4 and TSH level.

Item Type:	Article (Journal)
Additional Information:	5471/35526
Subjects:	R Medicine > R Medicine (General) R Medicine > RC Internal medicine
Kulliyyahs/Centres/Divisions/Institutes (Can select more than one option. Press CONTROL button):	Kulliyyah of Medicine > Department of Internal Medicine
Depositing User:	Dr Mohammad Arif Shahar
Date Deposited:	19 Mar 2014 09:16
Last Modified:	16 Apr 2014 17:58
URI:	http://irep.iium.edu.my/id/eprint/35526

Actions (login required)

View Item